DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 204268
NDA 204268 describes TESTOSTERONE, which is a drug marketed by Actavis Labs Ut Inc, Perrigo Israel, Ani Pharms Inc, Par Pharm, Perrigo Uk Finco, Watson Labs, Cipla Ltd, Lupin Ltd, Hikma Farmaceutica, Luitpold Pharms Inc, Mylan Institutional, Paddock Llc, Sandoz Inc, Sun Pharm Inds Ltd, Watson Pharms Inc, West-ward Pharms Int, Bel Mar, Elkins Sinn, and Lilly, and is included in forty-two NDAs. It is available from six suppliers. Additional details are available on the TESTOSTERONE profile page.
The generic ingredient in TESTOSTERONE is testosterone propionate. There are sixty-three drug master file entries for this compound. Additional details are available on the testosterone propionate profile page.
The generic ingredient in TESTOSTERONE is testosterone propionate. There are sixty-three drug master file entries for this compound. Additional details are available on the testosterone propionate profile page.
Summary for 204268
| Tradename: | TESTOSTERONE |
| Applicant: | Perrigo Israel |
| Ingredient: | testosterone |
| Patents: | 0 |
| Therapeutic Class: | Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers) |
| Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 204268
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | GEL, METERED;TRANSDERMAL | Strength | 1.62% (20.25MG/1.25GM ACTUATION) | ||||
| Approval Date: | Aug 4, 2015 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
